Scheindlin et al., 2008-12: A narrative history of methylene blue that states Ehrlich and Guttmann gave it to two malaria patients in a Berlin hospital in 1891, with positive results 'though not equal to those with quinine', and describes Ehrlich's earlier finding of a selective affinity of the dye for nerve cells and nerve fibre endings.
Ehrlich and Guttmann, in 1891, administered MB as a treatment for malaria, on two patients in a Berlin hospital. The results were positive, though not equal to those with quinine
Scheindlin et al., 2008-12: A narrative history of methylene blue that states Ehrlich and Guttmann gave it to two malaria patients in a Berlin hospital in 1891, with positive results 'though not equal to those with quinine', and describes Ehrlich's earlier finding of a selective affinity of the dye for nerve cells and nerve fibre endings. C4 – review/essay (secondary), PubMed PMID 19144897. It gives the correct N = 2 and the correct clinical caveat (inferior to quinine), so it supports the fact of the 1891 trial but not the superlative 'first synthetic drug', which it does not use. It also records Wood's 1904 'meta-analysis' of 425 cases from eleven reports with 362 (85%) 'final cures' and 31 relapses, and Ehrlich's earlier clinical trial of methylene blue with a physician named Lippmann in neuralgia and arthritis, which produced analgesia but tended to damage the kidneys on continuous use. That Lippmann episode is dated only vaguely ('soon after') and is not a substitute for the unopened Ehrlich 1886 paper. Fetch route: CLOCKSS preserved copy of the ASPET journal page, HTML fetched with curl; excerpt cut from that HTML. The same text is also on the publisher's site (molinterv.aspetjournals.org/content/8/6/268). Study type: review.
